Distinguished in Chronic B-Cell Leukemia (CBCL)

Carol E. Moreno

Barcelona, CT, ES 
Distinguished in Chronic B-Cell Leukemia (CBCL)
Barcelona, CT, ES 
OverviewLocationsClinical Research

Overview

Carol Moreno practices in Barcelona, Spain. Ms. Moreno is rated as a Distinguished expert by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). Her top areas of expertise are Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), and Leukemia.

Her clinical research consists of co-authoring 91 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 76 articles and participated in 1 clinical trial in the study of Chronic B-Cell Leukemia (CBCL).

Gender
Female

Locations

Barcelona, CT, Spain
Other Locations
Bellaterra, CT, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Multicenter, Non-randomized, Open Label Study to Evaluate the Efficacy and Security of Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
A Multicenter, Non-randomized, Open Label Study to Evaluate the Efficacy and Security of Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Enrollment Status: Unknown
Publish Date: September 16, 2022
Intervention Type: Drug
Study Drug: Ibrutinib
Study Phase: Phase 2

91 Total Publications

Risk scores predicting disease progression in early-stage chronic lymphocytic leukemia: Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy.
Risk scores predicting disease progression in early-stage chronic lymphocytic leukemia: Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy.
Journal: Cancer
Published: June 07, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Moreno's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile